ProPhase Labs Inc (PRPH)

Currency in USD
0.466
+0.045(+10.68%)
Closed·
After Hours
0.470+0.004(+0.84%)
·
PRPH Scorecard
Full Analysis
Operates with a significant debt burden
Earnings results expected in 12 days
Fair Value
Day's Range
0.4210.479
52 wk Range
0.2183.290
Key Statistics
Prev. Close
0.422
Open
0.43
Day's Range
0.421-0.479
52 wk Range
0.218-3.29
Volume
1.02M
Average Volume (3m)
2.25M
1-Year Change
-84.62%
Book Value / Share
0.5
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PRPH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

ProPhase Labs Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

ProPhase Labs Inc Company Profile

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer’s disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

ProPhase Labs Inc Earnings Call Summary for Q1/2025

  • ProPhase Labs beats Q1 2025 EPS forecast (-$0.13 vs -$0.18), despite revenue miss ($1.43M vs $2.45M); stock rises 5.74% to $0.339
  • Significant operational restructuring: workforce reduced from 96 to 25, manufacturing facility sold, genomics lab closed to cut costs
  • Company anticipates major liquidity events in H2 2024, including potential cash from Crown Medical collections and possible Nebula Genomics sale
  • CEO expresses confidence in raising stock price through incoming funds; emphasizes value of genomic dataset to research companies
  • Challenges remain: revenue generation, new product commercialization, evolving market conditions for genomic and COVID testing
Last Updated: 20/05/2025, 16:24
Read Full Transcript

Compare PRPH to Peers and Sector

Metrics to compare
PRPH
Peers
Sector
Relationship
P/E Ratio
−0.4x−0.7x−0.5x
PEG Ratio
0.010.010.00
Price/Book
1.3x1.6x2.6x
Price / LTM Sales
3.3x1.8x3.2x
Upside (Analyst Target)
-110.9%41.7%
Fair Value Upside
Unlock16.2%6.1%Unlock

Earnings

Latest Release
May 20, 2025
EPS / Forecast
-0.13 / -0.18
Revenue / Forecast
1.43M / 2.45M
EPS Revisions
Last 90 days

PRPH Income Statement

People Also Watch

1.23
KLTO
-3.15%
2.130
ONDS
-0.47%
7.200
GVH
-0.69%
2.25
BMGL
+0.45%

FAQ

What Stock Exchange Does ProPhase Labs Trade On?

ProPhase Labs is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for ProPhase Labs?

The stock symbol for ProPhase Labs is "PRPH."

What Is the ProPhase Labs Market Cap?

As of today, ProPhase Labs market cap is 19.36M.

What Is ProPhase Labs's Earnings Per Share (TTM)?

The ProPhase Labs EPS (TTM) is -1.97.

When Is the Next ProPhase Labs Earnings Date?

ProPhase Labs will release its next earnings report on 06 Aug 2025.

From a Technical Analysis Perspective, Is PRPH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has ProPhase Labs Stock Split?

ProPhase Labs has split 2 times.

How Many Employees Does ProPhase Labs Have?

ProPhase Labs has 96 employees.

What is the current trading status of ProPhase Labs (PRPH)?

As of 26 Jul 2025, ProPhase Labs (PRPH) is trading at a price of 0.47, with a previous close of 0.42. The stock has fluctuated within a day range of 0.42 to 0.48, while its 52-week range spans from 0.22 to 3.29.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.